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Brody Recognized for Promising Pancreatic Cancer Research

Assistant Professor Jonathan Brody, PhD, has received a prestigious Career Development Award from the
Pancreatic Cancer Action Network (PanCAN) and the American Association for Cancer Research (AACR)
for his innovative research in pancreatic cancer.
One of three Career Development Awards granted to junior faculty at academic and medical institutions
each year, Dr. Brody’s award is named for the philanthropist and Rydex Investments founder Skip Viragh,
who died of pancreatic cancer in 2003. Dr. Brody accepted the award at a formal ceremony held on April
20 at the annual meeting of the AACR in Washington, DC. He will receive $200K over the next two years.
“While the need for scientific and medical breakthroughs in pancreatic cancer research is urgent, there is
a major shortage of federal funding for research on this deadly disease,” says Julie Fleshman, President
and CEO of PanCAN. “Since 1999, PanCAN has been working to help fill this critical void. In 2010, we will
disburse nearly $2.3 million in funding for research grants. We are excited about this partnership with Dr.
Brody and look forward to working with him as we make strides against this deadly disease.”
Dr. Brody will use the funding to build upon his research on a stress-response protein called Hu antigen R
(HuR), “activated” in pancreatic tumor cells. Dr. Brody and his team have found that HuR can actually be
used to predict the effectiveness of the standard chemotherapy treatment for pancreatic cancer:
gemcitabine.
“This means that HuR is essentially a biomarker, which we can use to determine up front whether a
patient is likely to respond to this treatment or not,” says Dr. Brody. The findings of his initial study, of
which Dr. Brody was the senior author and Jefferson pathologist Dr. Agnieszka Witkiewicz closely
collaborated on, were first published as a Priority Report in the journal Cancer Research in June 2009. A
follow up report is being presented this month at the American Surgical Association in Chicago.

“By improving our understanding of drug metabolism and the molecular diversity that exists within the
patient population, this study has important implications for the development of personalized medicine
for pancreatic cancer,” notes Ms. Fleshman. “The results have the potential to help us learn how to
customize treatments for patients to improve outcomes and survival.”
Dr. Brody and his team are now seeking a way to activate HuR in patients that show low levels of the
protein. “The research is moving into expanding our clinical samples as well as building on pre-clinical
animal models for further exploration,” says Dr. Brody. “We are intrigued as to whether other
chemotherapeutic agents might also engage this same pathway.”
“As a young pancreatic cancer researcher I have always admired these two topnotch organizations,” says
Dr. Brody, “and to be recognized by them truly is an honor and validates the direction of my research.” This
award allows him to produce a body of high-quality data over the next few years as he strives to extend
his funding and work with the aid of such agencies as the National Cancer Institute (NCI). Ultimately, Dr.
Brody hopes this funding will help translate the work in his laboratory for the benefit of pancreatic cancer
patients in the clinical setting.
[Editor’s note: Dr. Brody has, as of this writing, just been notified that he has been awarded an American
Cancer Society grant in excess of $700k over the next 4 years.]
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Overview

Changing Lives Through Research
Katie Ashburn, CRNP,
and Shawn Pierce, CNRP,

surgery fellowship at Jefferson; Pramila
Anné, MD, Associate Professor of
Radiation Oncology; Neal Flomenberg,
MD, Chair of Medical Oncology; and
Barbara Cavanaugh, MD, Clinical
Associate Professor of Radiology, in
Breast Imaging. Other critical team
members are administrator Rosanne
Iacono, RN-C, MSN, CRNP, and
coordinator Rita Battaglini, RN, BSN,
who helps patients navigate the complex
insurance system.

Charles J. Yeo, MD
Samuel D. Gross Professor and
Chair, Department of Surgery

Progress…Service Lines
Many in the Department have been involved
with our institutional efforts initiating five
robust service lines here at Jefferson.
These service lines are co-directed by a
physician and an administrator, supported
by Executive Committees and Working
Committees, and focused upon five specific
areas of clinical activity:
• Cancer
• Cardiovascular
• GI/Transplant
• Neurology/Neurosurgery
• Musculoskeletal
Our surgeons touch each of these areas,
serve on their committees, and have helped
direct initiatives dealing with quality and
outcomes, growth of services, recruitments,
marketing, etc. These service lines cross the
traditional departmental silos, bring together
physicians, surgeons and administrators
who are focused on care in the given clinical
areas, and have proved, even early in
their existence, to be valuable as we look
to grow, expand our imprint, and prepare
for Jefferson’s medicine of the future.
Of note, these service lines also provide
opportunities for focused multidisciplinary
training of our residents, students and
fellows…in one of the five clinical areas
mentioned above.
Additionally, a sixth, more “informal” service
line deals with the Multidisciplinary Center
for Critical Care. Recently new critical care
beds have been built both at the Jefferson
Hospital of Neuroscience (JHN) and on the
4th floor of the Gibbon Building, ushering in
a more robust opportunity for us to care for
the increasingly ill and complex patients that
are being treated here. As Thomas Jefferson
said in 1810, “As new discoveries are
made…institutions must advance also, and
keep pace with the times.”
Boy, are there changes afoot!
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Center director Gordon Schwartz, MD, MBA, FACS and assistant director Sun Yong (Sunny)
Lee, MD, FACS lead the multidisciplinary team of the new Jefferson Breast Care Center.

The New Breast Care
Center: Truly “Managed
Care” for Women
In a few short months, the Jefferson Breast
Care Center has already distinguished
itself nationally. Formally launched on
October 1, 2009, with the appointment
of Gordon Schwartz, MD, MBA, FACS
as Center Director, the Center also
received a full, 3-year accreditation from
the National Accreditation Program for
Breast Care Centers (NABCC) after a
rigorous evaluation.
The Center offers a unique approach to
the care of any woman with questions
related to breast health. “We want to
serve people with specific diagnoses, but
also strengthen our commitment to those
whom we call ‘the worried well’,” says
Dr. Schwartz, a Professor of Surgery.

“We want to serve people
with specific diagnoses,
but also strengthen
our commitment to
those whom we call
‘the worried well’”
The Center’s multidisciplinary approach
integrates surgery, medicine, oncology,
and radiation oncology, as well as
integrative (and holistic) medicine and
emotional support for women and their
families. The Jefferson model coordinates
and streamlines the process for patients,

to avoid what one patient described as her
experience elsewhere of “being treated by
4 or 5 subcontractors, when what I really
wanted was a general contractor.”
The team of Jefferson specialists includes
the new Assistant Director, Sun Yong
Lee, MD, FACS who completed a breast

Dr. Schwartz is committed to making
the most of what scientists are doing
across campus, “by integrating basic
science results into our practice as soon
as possible.” The Center will also have an
international board of advisors, including
the world-renowned Italian breast cancer
surgeon Umberto Veronesi, MD, and
others from Italy, France and the United
Kingdom, making Jefferson a site for
international collaboration.
The long-term plan for the center is to
expand upon the Breast Imaging Center
on the 4th floor of the Medical Office
Building at 11th and Walnut Streets in
Center City by adding a clinical facility
one floor below. From its leadership to
individual technicians, the Center staff
strives to serve as a lifelong family for its
patients. “The women we treat will have a
home with us forever,” says Dr. Schwartz.
For more information about the Breast Care
Center visit: www.jeffersonhospital.org/breast

Please Welcome
Joyce Hartmann, Physician Liaison
for Liver Transplant Program
This fall marked the 25th anniversary
of the region’s first liver transplant –
performed at Jefferson – and since then,
Joyce Hartmann has had the opportunity
to represent Jefferson’s Liver Transplant
Program to referring physicians throughout
the Delaware Valley.
With 20 years of healthcare marketing
and program development experience,
Joyce was attracted to the position
because of the chance to represent the
multidisciplinary team of physicians
and surgeons, transplant coordinators,
social workers and support staff.
Jefferson’s Liver Transplant Program
consistently surpasses national averages
for transplantation survival rates,” Joyce
explains. “Our surgeons transplant the
sickest patients in the region and our
program has the lowest mortality rate
among patients on the recipient waiting list.
It is a privilege to represent the team, to

ensure that their talents are known to referring
physicians and patients receive the care that
they need.”
To coordinate an office visit and for
assistance with patient navigation or
scheduling an appointment, please
contact Joyce at 215-503-7507 or
joyce.hartmann@jeffersonhospital.org.

On the Job

are Vascular Surgery Nurse Practitioners
for the outpatient and inpatient practices
(respectively). They both assumed their
positions in late spring of 2009.
What does an average day look like?
Katie: Between the vascular attending

physicians and me, we see 40 patients
a day in a fast-paced outpatient office.
I perform patient history and physicals
and develop a plan of care in conjunction
with the attendings, to improve patient
education and communication. I follow
wound care patients and occasionally
manage insurance issues. We work closely
with the anticoagulation clinic and the
hyperbaric treatment center.
Shawn: I work with the vascular team

Jonathan Brody, PhD, and his team of technicians, residents and students are
conducting studies that are garnering financial support for a historically underfunded
field of research – pancreatic cancer.

Brody Recognized for Promising
Pancreatic Cancer Research
Assistant Professor Jonathan Brody,
PhD, has received a prestigious Career
Development Award from the Pancreatic
Cancer Action Network (PanCAN) and
the American Association for Cancer
Research (AACR) for his innovative
research in pancreatic cancer.

“The results have the
potential to help us
learn how to customize
treatments for patients
to improve outcomes
and survival.”
One of three Career Development Awards
granted to junior faculty at academic and
medical institutions each year, Dr. Brody’s
award is named for the philanthropist and
Rydex Investments founder Skip Viragh,
who died of pancreatic cancer in 2003.
Dr. Brody accepted the award at a formal
ceremony held on April 20 at the annual
meeting of the AACR in Washington,
DC. He will receive $200K over the next
two years.

“While the need for scientific and
medical breakthroughs in pancreatic
cancer research is urgent, there is a
major shortage of federal funding for
research on this deadly disease,” says
Julie Fleshman, President and CEO of
PanCAN. “Since 1999, PanCAN has been
working to help fill this critical void. In
2010, we will disburse nearly $2.3 million
in funding for research grants. We are
excited about this partnership with
Dr. Brody and look forward to working
with him as we make strides against
this deadly disease.”

comprised of an intern, a resident, a
fellow and Drs. Paul DiMuzio and Joshua
Eisenberg. Together we manage patients
in surgery as well as on the floor. I work
closely with our case manager on more
complicated discharge cases. After
patients leave, I call to help with questions
or complications.

Surgical Intensive Care Unit for 3½ years.
I earned my master’s degree at Jefferson
during that time.
Shawn: I have been a nurse for 23 years

and I taught for 10, so many of the nurses
here know me as an instructor. I worked
as a critical care “float” RN working in
the Intensive Care Units and the Post
Anesthesia Care Unit as needed.
Do the two of you work together?

What are your respective backgrounds?

Shawn: We share an office and often

Katie: I worked as a nurse at Jefferson for

confer with each other to improve
continuity in patient care. Patients
appreciate how well we know them.

5 years, including the Intermediate Surgical
Intensive Care Unit for 18 months and the

author and Jefferson pathologist Dr.
Agnieszka Witkiewicz closely collaborated
on, were first published as a Priority
Report in the journal Cancer Research in
June 2009. A follow up report is being
presented this month at the American
Surgical Association in Chicago.

Dr. Brody will use the funding to build
upon his research on a stress-response
protein called Hu antigen R (HuR),
“activated” in pancreatic tumor cells.
Dr. Brody and his team have found
that HuR can actually be used to
predict the effectiveness of the standard
chemotherapy treatment for pancreatic
cancer: gemcitabine.

“By improving our understanding of
drug metabolism and the molecular
diversity that exists within the patient
population, this study has important
implications for the development of
personalized medicine for pancreatic
cancer,” notes Ms. Fleshman. “The results
have the potential to help us learn how
to customize treatments for patients to
improve outcomes and survival.”

“This means that HuR is essentially
a biomarker, which we can use to
determine up front whether a patient is
likely to respond to this treatment or not,”
says Dr. Brody. The findings of his initial
study, of which Dr. Brody was the senior

Dr. Brody and his team are now seeking a
way to activate HuR in patients that show
low levels of the protein. “The research
is moving into expanding our clinical
samples as well as building on pre-clinical
animal models for further exploration,”

says Dr. Brody. “We are intrigued as to
whether other chemotherapeutic agents
might also engage this same pathway.”
“As a young pancreatic cancer researcher
I have always admired these two topnotch organizations,” says Dr. Brody,
“and to be recognized by them truly is
an honor and validates the direction of
my research.” This award allows him to
produce a body of high-quality data over
the next few years as he strives to extend
his funding and work with the aid of such
agencies as the National Cancer Institute
(NCI). Ultimately, Dr. Brody hopes this
funding will help translate the work in his
laboratory for the benefit of pancreatic
cancer patients in the clinical setting.
[Editor’s note: Dr. Brody has, as of this
writing, just been notified that he has
been awarded an American Cancer Society
grant in excess of $700k over the next
4 years.]

For more information about the
Liver Transplant Program visit:
www.jeffersonhospital.org/transplant/liver
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